Last reviewed · How we verify

NCT05219201: CRYOSEP

Effectiveness of Cryotherapy on the Fatigue of Patients With Multiple Sclerosis

Completed NA Last updated 17 April 2026
What this trial tests

NA trial testing partial-body cryotherapy chamber session in Multiple Sclerosis in 43 participants. Completed in 11 July 2025.

Timeline
12 September 2022
Primary endpoint
30 June 2024
11 July 2025

Quick facts

Lead sponsorFondation Ildys
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment43
Start date12 September 2022
Primary completion30 June 2024
Estimated completion11 July 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Fondation Ildys

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

the aim of the study is to evaluate the effectiveness of partial-body cryotherapy (PBC) on the symptoms of patients with multiple sclerosis during a rehabilitation stay.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

Other Fondation Ildys trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05219201.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing